Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

What Starbucks (SBUX)'s Dividend Hike And MUSH Foods Deal Mean For Shareholders

View original at finance.yahoo.com
“Starbucks' narrative projects $45.5 billion revenue and $4.6 billion earnings by 2028.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Some of the most optimistic analysts were projecting Starbucks' revenue to reach about US$45,000,000,000 and earnings near US$4,300,000,000

    60% confidence

  • Starbucks' forecasts yield a $99.94 fair value, in line with its current price

    60% confidence

  • This requires 7.5% yearly revenue growth and about a $2.0 billion earnings increase from $2.6 billion today

    60% confidence

  • Starbucks' narrative projects $45.5 billion revenue and $4.6 billion earnings by 2028

    60% confidence

Data points we hold from this source

Starbucks Corporation · dividend per share0.62 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
What Starbucks (SBUX)'s Dividend Hike And MUSH Foods Deal Mean For Shareholders — Source | Via News | Via News